Iveta Najmanová
Charles University in Prague
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Iveta Najmanová.
Current Topics in Medicinal Chemistry | 2015
Iveta Najmanová; Martin Dosedel; Radomír Hrdina; Pavel Anzenbacher; Tomas Filipsky; Michal Ríha; Premysl Mladenka
Coumarins are a large group of substances, primarily of plant origin. Like their more intensively examined congeners flavonoids, many of them are antioxidants. Although such properties may be advantageous in cardiovascular diseases, it has been shown that coumarins exhibit direct effects on the cardiovascular system which are not based on antioxidant activity. The most common example is the well-known drug warfarin, a synthetic compound derived from natural dicoumarol. Moreover, other coumarins have been shown to possess antiplatelet and vasodilatory potential. Interestingly, the former effect may be mediated by the inhibition of various pathways leading to platelet aggregation, their differing effects on those pathways being due to structural differences between the various coumarins. Conversely, their vasodilatory potential is linked in the majority of cases to the inhibition of increases in intracellular calcium concentration in vascular smooth muscle cells, and in several coumarins also to NO-mediated vasodilatation. Available data on both activities are summarized in this review. At the end of this review, relevant data are provided from a few studies testing the in vivo effects of coumarins on major cardiovascular diseases; the clinical use of warfarin and other coumarin anticoagulants, as well as the limited data on the clinical use of coumarins in chronic venous insufficiency and the possible toxicological effects of coumarins.
Molecular Nutrition & Food Research | 2016
Iveta Najmanová; Jana Pourová; Marie Vopršalová; Veronika Pilařová; Vladimír Semecký; Lucie Nováková; Přemysl Mladěnka
There are reports of positive effects of quercetin on cardiovascular pathologies, however, mainly due to its low biovailability, the mechanism remains elusive. Here, we report that one metabolite formed by human microflora (3-(3-hydroxyphenyl)propionic acid)relaxed isolated rat aorta and decreased arterial blood pressure in rats.
International Journal of Pharmaceutics | 2018
Elena Piera Porcu; Massimo Cossu; Giovanna Rassu; Paolo Giunchedi; Guido Cerri; Jana Pourová; Iveta Najmanová; Thomas Migkos; Veronika Pilařová; Lucie Nováková; Přemysl Mladěnka; Elisabetta Gavini
Potential positive effects of flavonol quercetin on humans were suggested by many studies. However, it is not clear if these effects are mediated by quercetin or its metabolites. The in vivo confirmation of quercetin effects is largely hindered by its low water solubility and thus impossibility to test directly its impact. Therefore, a solid dispersion of quercetin with polyvinylpyrrolidone (PVP) was developed to prepare an injectable formulation of water-soluble quercetin. The optimized formulation provided a 20,000-fold increase in quercetin solubility. This formulation was tested on conventional and spontaneously hypertensive rats; it lowered their blood pressure in both short- and long-term basis. Pharmacokinetic data are also provided. This study reports for the first time an injectable water-soluble formulation of quercetin suitable for confirmation of its vascular effect in vivo.
Free Radical Biology and Medicine | 2014
Iveta Najmanová; Marie Vopršalová; Premysl Mladenka
A large number of studies confirmed antihypertensive effect of quercetin. However, due to its low bioavailability, the mechanism of action has been remaining vague and is not likely associated with its antioxidant effect. This study was designed to determinate if quercetin metabolites might be responsible for the activity. During the in vitro study, the vasorelaxant potency of different quercetin metabolites including small phenolic acids formed by bacterial microflora was tested. Metabolites at concentration 10(-7) to 10(-3) M were tested for relaxation of rat thoracic aorta rings precontracted by phenylephrine. Subsequently the most active structure was selected for in vivo experiments, when the effect on blood pressure and heart rate was monitored after i.v. administration in dose range from 0,2mg/kg to 25mg/kg. The most active structure, 3-(3-hydroxyphenyl)propionic acid, initiated vasorelaxation in concentration of 100nM while quercetin at 500nM. The major quercetin metabolite formed by human enzymes, 3-glucuronide, was almost inactive. During the in vivo study the 3-(3-hydroxyphenyl)propionic acid decreased systolic blood pressure even at dose of 1mg/kg without having an effect on heart rate at this dose. In conclusion, some of quercetin metabolites may have be partly responsible for vasorelaxant activity of orally administered quercetin.
Talanta | 2018
Veronika Pilařová; Kateřina Plachká; Lucia Chrenková; Iveta Najmanová; Přemysl Mladěnka; Frantisek Svec; Ondřej Novák; Lucie Nováková
Fast, selective, and sensitive ultra-high performance liquid chromatography method with tandem mass spectrometry detection for the determination of quercetin and its metabolites with various physico-chemical properties such as molecular weight, lipophilicity, and acid-base properties has been developed. These compounds included small hydrophilic phenolic acids and more lipophilic metabolites with preserved flavonoid structure in small amount of rat plasma. The developed method enables selective separation of phenolic acids and a pair of isomers tamarixetin and isorhamnetin with satisfactory peak shapes and a high sensitivity using mass spectrometry detection. In addition, two sample preparation procedures including protein precipitation and microextraction in packed sorbent (MEPS) were optimized. The sample acidification included in protein precipitation as well as optimizing of MEPS sorbents and elution solvents improved isolation of quercetin and related compounds from rat plasma. Finally, both methods developed for sample preparation were fully validated to demonstrate sufficient accuracy and precision and acceptable matrix effects. Both sample preparation approaches combined with mass spectrometry-based quantification allowed the simultaneous determination of quercetin and its metabolites from a small amount of biological samples of only 50 μL. Due to the fast and non-selective parallel sample preparation, the protein precipitation was eventually applied to plasma samples derived from pharmacokinetic studies.
Vascular Pharmacology | 2018
Jana Pourová; Iveta Najmanová; Marie Vopršalová; Thomas Migkos; Veronika Pilařová; Lenka Applová; Lucie Nováková; Přemysl Mladěnka
SCOPE The flavonoid quercetin reduces arterial blood pressure in animals and humans but the mechanisms remains elusive. The aim of this study was to test the activity of flavonoid microbial metabolites, which can participate on the final vasorelaxant effect. METHODS AND RESULTS Both ex vivo (isolated rat thoracic aorta and mesenteric artery) and in vivo (normotensive and spontaneously hypertensive rats) approaches were used in this study. 4-methylcatechol and 3,4-dihydroxyphenylacetic acid (DHPA) had greater vasorelaxant effects on mesenteric artery than 3-(3-hydroxyphenyl)propionic acid, the previously reported metabolite with vasorelaxant effect. In vivo testing confirmed their blood pressure decreasing effect given both as bolus and slow infusion. Their mechanism at molecular level was different. CONCLUSIONS This study is the first to show that flavonoid metabolites DHPA and 4-methylcatechol decrease arterial blood pressure and hence a mixture of microbial metabolites formed in the gastrointestinal tract may be responsible for or contribute to the effect of orally ingested quercetin.
Atherosclerosis | 2018
Barbora Vitverova; Katerina Blazickova; Iveta Najmanová; Matej Vicen; Radek Hyšpler; Eva Dolezelova; Ivana Nemeckova; Jurjen Duintjer Tebbens; Carmelo Bernabeu; Miguel Pericacho; Petr Nachtigal
BACKGROUND AND AIMS Increased plasma levels of soluble endoglin (sEng) were detected in patients with endothelial dysfunction-related disorders and hypercholesterolemia. In this study, we hypothesized that high levels of sEng accompanied by mild hypercholesterolemia could aggravate endothelial and vessel wall dysfunction and affect endoglin/eNOS signaling in mouse aorta. METHODS Three-month-old female transgenic mice on CBAxC57BL/6J background, with high levels of sEng (Sol-Eng+high HFD), and their littermates with low levels of sEng (Sol-Eng+low HFD), were fed a high fat diet for six months. Plasma samples were used for biochemical, ELISA and Luminex analyses of total cholesterol, sEng and inflammatory markers. Functional parameters of aorta were assessed with wire myograph 620M. Western blot analyses of membrane endoglin/eNOS signaling and endothelial dysfunction/inflammation markers in aorta were performed. RESULTS Functional analysis of aorta showed impaired KCl induced vasoconstriction, endothelial-dependent relaxation after the administration of acetylcholine as well as endothelial-independent relaxation induced by sodium nitroprusside in the Sol-Eng+high HFD group compared to the Sol-Eng+low HFD group. Ach-induced vasodilation after administration of l-NAME was significantly higher in the Sol-Eng+high HFD group compared to the Sol-Eng+low HFD group. The expression of endoglin, p-eNOS/eNOS, pSmad2/3/Smad2/3 signaling pathway was significantly lower in the Sol-Eng+high HFD group compared to the Sol-Eng+low HFD group. CONCLUSIONS The results indicate that long-term hypercholesterolemia combined with high levels of sEng leads to the aggravation of endothelial and vessel wall dysfunction in aorta, with possible alterations of the membrane endoglin/eNOS signaling, suggesting that high levels of soluble endoglin might be considered as a risk factor of cardiovascular diseases.
Atherosclerosis Supplements | 2018
Petr Nachtigal; Barbora Vitverova; Matej Vicen; Iveta Najmanová; Eva Dolezelova; Carmelo Bernabeu; Miguel Pericacho
Atherosclerosis | 2018
Iveta Najmanová; T. Migkos; J. Pourova; M. Voprsalova; P. Mladenka
Atherosclerosis | 2018
Barbora Vitverova; Katerina Blazickova; Iveta Najmanová; Matej Vicen; Miguel Pericacho; Petr Nachtigal